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Background/aim: Nevirapine is a reverse-transcriptase inhibitor widely used in combination therapy to treat HIV infection. Nevirapine
is extensively metabolized in the liver and CYP2B6 is mainly responsible for oxidation of 3-hydroxynevirapine (3-OH NVP). This study
aims to explore CYP2B6 activity by measuring 2-hydroxynevirapine (2-OH NVP) and 3-OH NVP in plasma and to identify factors
associated with nevirapine pharmacokinetic parameters.
Materials and methods: A total of 112 patients were recruited and treated with nevirapine-based antiretroviral therapy. Plasma
nevirapine and metabolite concentrations were assayed using high-performance liquid chromatography via liquid–liquid extraction.
Results: Thirty-nine (34.8%) of the patients had no 3-OH NVP detected in their plasma while 2-OH NVP was detected in all patients.
Metabolite concentrations were low compared to nevirapine. Positive correlations were observed between nevirapine and its metabolites,
2-OH NVP (P < 0.01) and 3-OH NVP (P = 0.012). Nevirapine concentration was decreased when concomitantly administered with
methadone. Univariate analysis showed that ALT level, AST level, and detection of 3-OH NVP were associated with nevirapine
pharmacokinetic parameters.
Conclusion: The variability of nevirapine pharmacokinetic parameters was caused by liver enzymes and the presence of 3-OH NVP
metabolites. The presence of 3-OH NVP can probably be used to distinguished CYP2B6 activity and efficacy of nevirapine in patients
with HIV infection.
Key words: Nevirapine, 2-hydroxynevirapine, 3-hydroxynevirapine

1. Introduction
Nevirapine is the first nonnucleoside reverse-transcriptase
inhibitor approved and is widely used in combination
therapy to treat HIV infection. In Malaysia, the defined
daily dose of nevirapine was 0.0145 per 1000 population
per day in 2010, which increased from 0.0144 in 2009 (1).
Malaysia is a country that has a concentrated HIV
epidemic based on the WHO classification with a
cumulative total of 79,855 people living with HIV at the
end of 2011 (2). In Malaysia, the government provides
first-line highly active antiretroviral therapy free of charge
to all eligible patients who are treated in government
hospitals. Apart from that, the Malaysian government
also implemented a harm reduction program in 2006.
The government’s approach to reducing HIV infection
has been successful because the notification rate of HIV
* Correspondence: szn_m@yahoo.com

decreased from 28.4 in 2002 to 23.4 in 2005 and to 12.2
cases per 100,000 of population in 2011 (2). In 2013,
Malaysia reported an average of 9 cases per day or 3393
new cases, given a cumulative total of 101,672 HIV cases
with 20,235 AIDS cases and 16,340 deaths related to HIV/
AIDS, thus giving a reported total of 85,332 people living
with HIV (3).
Nevirapine acts by binding directly to the reverse
transcriptase and blocks the RNA- and DNA-dependent
polymerase activities by causing a disruption of the
enzyme’s catalytic site. Nevirapine is extensively
metabolized in the liver mainly by 2-, 3-, 8-, and
12-hydroxylation followed by glucuronidation of these
hydroxyl metabolites. Studies of the biotransformation
of nevirapine by human liver microsomes showed
that CYP2B6 is mainly responsible for oxidation of
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3-hydroxynevirapine (3-OH NVP) and CYP3A4 for 2and 12-hydroxynevirapine (2- and 12-OH NVP), while
2D6 mediates oxidation for 8- and 12-hydroxynevirapine
and CYP3A5 is a minor contributor in the oxidation of 2and 12-OH NVP (4). A single nucleotide polymorphism
(SNP) in exon 4 (G516T) is associated with a significant
reduction in CYP2B6 catalytic activity (5). Researchers also
associated nevirapine concentrations with CYP2B6 516
in several populations, such as Ugandans, HIV-infected
Thai women, and the Swiss population (6–8). However,
the correlation of nevirapine metabolites with CYP2B6
activity is unknown. Thus, this study explored CYP2B6
activity by measuring 2-OH and 3-OH NVP in plasma and
identified the associations between the presence of 3-OH
NVP and nevirapine pharmacokinetic parameters.
2. Materials and methods
2.1. Subjects
The study was conducted following approval from the
Human Research Ethics Committee, University Sains
Malaysia, and the Malaysia Ministry of Health Research
Ethical Committee. One hundred and twelve HIV patients
from three state hospitals in Malaysia were recruited. To be
included in the study, candidates had to be HIV-positive,
more than 18 years old, and started on nevirapine (200 mg
twice daily) at least 2 months prior to the pharmacokinetic
sampling in order to achieve steady-state conditions. All
participants provided written informed consent before
participation.
2.2. Nevirapine quantification
Plasma concentrations of 2-OH NVP, 3-OH NVP, and
nevirapine were quantified using HPLC-UV analysis
(Agilent 1200 series HPLC system with DAD detector)
via a method previously described (9). The nevirapine
and metabolites were extracted using the liquid–liquid
extraction method with 4 mL of diethyl ether and 1 mL
of hexane. The limits of detection were 0.5 µg/mL, 0.02
µg/mL, and 0.015 µg/mL for nevirapine, 2-OH NVP, and
3-OH NVP, respectively. Linear regression analysis data
for the calibration plot showed good linear relationships
between response and concentration for nevirapine and
the oxidative metabolites with regression coefficient values
of r2 > 0.99. Briefly explained, each plasma aliquot of 1 mL
was heated at 56 °C for 90 min to inactivate the HIV-1
virus and was spiked with carbamazepine as an internal
standard. Chromatographic separation of the compounds
was accomplished using a Zorbax SB-C8 column and
a mobile phase consisting of ammonium acetate and
acetonitrile (8:2 v/v). Detection was performed at 280 nm
and peaks were quantified at 5.87 min for 2-OH NVP, 7.42
min for 3-OH NVP, 12.88 min for nevirapine, and 26 min
for the internal standard.
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2.3. Blood sampling
Blood samples were drawn at 0, 0.5, 1, 1.5, 2, 3, 4, and 8
h after the morning dose. We assumed that all patients
had identical predose and 12-h postdose levels. The AUC
of nevirapine was obtained using the trapezoid rule with
linear interpolation with a noncompartmental model
with PK-Solver. The minimum plasma concentration
(Cmin) and maximum plasma concentration (Cmax) of
nevirapine were obtained from visual inspections of the
concentration–time curves.
2.4. Statistical methods
The target variables in our study were Cmax, Cmin, and
AUC. All statistical tests were performed using SPSS 22
(IBM Corp., Armonk, NY, USA). Normality distribution
and equality of variance were determined prior to statistical
analysis. Univariate analyses were done using simple
linear regression, the independent t-test, or the Mann–
Whitney U test. Correlations between the concentrations
of nevirapine and its metabolites were tested using
the Pearson correlation. From the results of univariate
analyses, independent variables that had a P-value of <0.25
were included in the multiple linear regression analysis. P
< 0.05 was accepted as significant.
3. Results
Patients’ characteristics at the time of sampling are
summarized in Table 1. Among the 112 patients recruited,
39 of them had no 3-OH NVP detected in their plasma
while 2-OH NVP was detected in all patients. Nearly an
equal number of male and female patients were recruited
Table 1. Patients’ characteristics at the time of sampling.
Patients’ characteristics

n [%]

Sex, n [%]
Male
Female

63 [56.3%]
49 [43.8%]

Age (years), median [range]

40 [19–65]

BMI (kg/m2), median [range]

21.2 [15.41–39.06]

Weight (kg), median [range]

58.1 [37.5–102.5]

CD4 count (cell/mm ), median [range]

373 [90–1376]

AST, mean [SD]

37.71 [17.95]

ALT, mean [SD]

35.52 [28.21]

Viral load (copies/mL), n [%]
Not detected
<34
≥34

60 [53.6%]
30 [26.8%]
22 [19.6%]
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and median BMI was 21.2 kg/m2. Eighty percent of the
patients had undetectable viral loads or had less than 34
copies/mL at the time of study, and CD4 T cell counts
ranged from 90 to 1376 cell/mm3. Seventeen of the
patients were on methadone replacement therapy and
seven patients were on isoniazid preventive therapy. Five
of the patients were coinfected with the hepatitis B/C virus.

Correlations between nevirapine and its metabolites and
the metabolite ratio are shown in Table 2. Factors associated
with nevirapine pharmacokinetic parameters are shown
in Tables 3–5. There was considerable interindividual
variability in the nevirapine plasma concentrations at
Cmax, ranging from a minimum value of 2.01 µg/mL to a
maximum value of 24.32 µg/mL.

Table 2. Metabolic ratios and correlation of plasma hydroxyl nevirapine with nevirapine in HIV-infected patients.
Mean concentration, µmol (SD)

#
a

Metabolic ratio

r value#

P-valuea

Nevirapine

31.332 (12.82)

2-OH NVP

1.364 (0.64)

0.04

0.789

<0.01

3-OH NVP

0.125 (0.067)

0.004

0.294

0.012

Correlation between nevirapine hydroxyl metabolites and nevirapine.
Pearson correlation was applied.

Table 3. Predictors of nevirapine Cmin analysis with multiple linear regression with the stepwise method.

Variables

b (95% CI)

Univariate
analysis
P-valuea

Age

0.041 (–0.014, 0.097)

0.145

Weight

–0.002 (–0.038, 0.033)

0.894

BMI

–0.011 (–0.105, 0.083)

0.821

CD4 count

–0.001 (–0.004, 0.001)

0.298

ALT

0.021 (0.005, 0.038)

0.01*

AST

0.03 (0.005, 0.056)

0.021*

3-OH metabolic ratio

–29.60 (–204.85, 145.65)

0.738

2-OH metabolic ratio

–23.12 (–55.96, 9.72)

0.166

Median (IQR) µg/mL

P-valueb

Sex
Male
Female

5.63 (2.63)#
5.12 (2.35)

0.295

Viral load detection
Yes
No

5.49 (2.43)
5.48 (2.66)

0.993

3-OH detection
Yes
No

5.26 (2.33)
4.88 (2.89)

0.088c

Methadone
Yes
No

4.46 (3.68)
5.26 (2.45)

0.096c

Multiple linear regression analysis
Adjusted b (95% CI)

t-stat

P-value

0.021 (0.005, 0.037)

2.614

0.01*

0.971 (0.021, 1.92)

2.026

0.045*

Simple linear regression. b Mann–Whitney test. c Independent t-test. *Significant.
aminotransferase, AST = aspartate aminotransferase, BMI = body mass. index
a

#

Presented as mean (SD). ALT = alanine
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Table 4. Predictors of nevirapine Cmax analysis with multiple linear regression with the stepwise method.

Variables

b (95% CI)

Univariate
analysis
P-valuea

Age

0.056 (–0.02, 0.132)

0.147

Weight

–0.023 (–0.071, 0.025)

0.351

BMI

–0.002 (–0.005, 0.001)

0.226

CD4 count

–0.091 (–0.218, 0.035)

0.155

ALT

0.037 (0.016, 0.059)

0.01*

AST

0.046 (0.011, 0.081)

0.01*

3-OH metabolic ratio

–131.35 (–368.07, 105.38)

0.274

2-OH metabolic ratio

–36.31 (–80.76, 8.13)

0.108

Median (IQR) µg/mL

P-valueb

Sex
Male
Female

8.73 (3.55)#
7.83 (3.19)

0.167c

Viral load detection
Yes
No

8.42 (3.23)
8.49 (3.64)

0.919

3-OH detection
Yes
No

8.21 (3.42)
7.09 (4.46)

0.196

6.53 (4.87)
8.11 (3.46)

0.086

Methadone
Yes
No
a

Simple linear regression. b Mann–Whitney test.

c

Adjusted b (95% CI)

t-stat

P-value

0.037 (0.015, 0.058)

3.313

0.001*

Independent t-test. *Significant. # Presented as mean (SD).

4. Discussion
CYP2B6 variants have been associated with 4-fold higher
nevirapine concentrations in plasma (8). As mentioned
earlier, nevirapine is metabolized in the liver primarily
by CYP3A4 and CYP2B6 for 2-OH and 3-OH NVP,
respectively. In this study, we measured nevirapine,
2-OH NVP, and 3-OH NVP plasma concentrations and
justified the CYP2B6 activity by using the 3-OH NVP
plasma concentration as a marker. Since the limits of
detection for 2-OH and 3-OH NVP were 0.02 µg/mL
and 0.015 µg/mL, respectively, concentrations detected
below the limit were considered to be undetected. 2-OH
NVP was detected in all patients; however, in only 73
of them was it detected together with 3-OH NVP. For
the metabolite ratio, concentrations of 2-OH and 3-OH
NVP at the Tmax of nevirapine were compared with the
nevirapine concentration. Concentrations were converted
to micromolar units by dividing the 2-OH NVP, 3-OH
NVP, and nevirapine concentrations (µg/mL) into a
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Multiple linear regression analysis

molecular weight of 282 for hydroxynevirapine and 266
for nevirapine.
Fan-Havard et al. (10) demonstrated lower
concentrations of nevirapine metabolites when comparing
pharmacokinetic parameters of nevirapine between
a single dose of nevirapine in HIV-negative African
Americans and nevirapine at steady state in HIVinfected Cambodian patients. Our study showed similar
findings. The metabolite ratios of 2-OH and 3-OH
NVP examined were 0.04 and 0.004, respectively, which
are 25 times and 250 times lower than the parent drug.
The predominant metabolite was 2-OH NVP, which is
contrary to the Cambodian population, where the 3-OH
NVP plasma concentration was higher than that of 2-OH
NVP. Further analysis showed positive correlations
between concentrations of nevirapine and its metabolites.
Strong correlations were observed between 2-OH NVP
and nevirapine concentrations while 3-OH NVP and
nevirapine demonstrated weak correlations. In a study to
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Table 5. Predictors of nevirapine AUC analysis with multiple linear regression with the stepwise method.

a

Variables

b (95% CI)

Univariate
analysis
P-valuea

Age

0.571 (–0.163, 1.305)

0.126

Weight

–0.147 (–0.615, 0.322)

0.537

BMI

–0.654 (–1.885, 0.577)

0.295

CD4 count

–0.016 (–0.047, 0.015)

0.302

ALT

0.362 (0.151, 0.572)

0.001*

AST

0.507 (0.173, 0.842)

0.003*

3-OH metabolic ratio

–1179.23 (–3476.60, 1118.144)

0.311

2-OH metabolic ratio

–391.318 (–821.105, 38.469)

0.074

Median (IQR) mg h/L

P-valueb

Sex
Male
Female

74.69 (42.19)
71.01 (37.21)

0.093

Viral load detection
Yes
No

74.69 (38.63)
71.30 (32.38)

0.464

3-OH detection
Yes
No

72.79 (33.75)
67.41 (45.67)

0.131

Methadone
Yes
No

62.47 (60.44)
74.57 (32.42)

0.051

Multiple linear regression analysis
Adjusted b (95% CI)

t-stat

P-value

0.518 (0.254, 0.782)

3.893

<0.001*

Simple linear regression. b Mann–Whitney test. *Significant.

assess the pharmacokinetics of nevirapine and metabolites
in patients with hepatic fibrosis, the metabolite profiles
were comparable across the stages of the disease (11).
Risk of virological failure increased 5-fold when
nevirapine concentrations were below 3 mg/L and dose
adjustment has been suggested if the nevirapine Cmin
is lower than 3 mg/L (12,13). Our results show that
higher trends of nevirapine plasma concentration were
demonstrated in patients with 3-OH NVP for both Cmax
and Cmin. However, a significant difference was only
observed in Cmin. Although not statistically significant,
a higher trend was also observed in the area under the
plasma drug concentration–time curve (AUC 0–12 h)
in patients with 3-OH NVP. The AUC reflects the actual
body exposure to drugs after the administration of a dose
of the drug. The comparison of nevirapine concentrations
provides insight into nevirapine disposition, which may
be related to variants in the CYP2B6 gene involved in the
formation of 3-OH NVP.

Comparing the concentrations and AUC 0–12 h of
nevirapine, no difference was observed between groups of
patients with detected and undetected viral load. However,
the majority of them (71%) had a viral load detected of less
than 34 copies/mL.
Nevirapine was previously reported to decrease
the concentration and efficacy of methadone (14). To
our knowledge, no study has yet reported the effects
of concomitant administration of methadone on the
nevirapine concentration. In the current study, the
nevirapine concentrations and AUC following twice daily
doses of nevirapine at 200 mg were lower when it was taken
concomitantly with methadone (Tables 3–5). Although
not statistically significant, the percentage lowered
was 16% in the AUC, 15% in Cmin, and up to 19.5% in
Cmax. A previous study demonstrated that CYP2B6 is
also responsible in the metabolism of methadone and
this might explain the drug–drug interaction between
nevirapine and methadone, particularly in concentrations
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and AUC, as observed in the current study (15). It is
suggested to perform nevirapine plasma concentration
monitoring as methadone may influence the efficacy
of treatment because it causes a decrease in nevirapine
concentrations.
Elevated AST levels, age, and weight are identified
factors contributing to a high interindividual variance of
nevirapine (12,14,16–19). In our study, univariate analysis
showed that the AST and ALT levels were significantly
associated with nevirapine concentrations and AUC 0–12
h. Furthermore, multivariate analyses confirmed that
increased ALT levels significantly increased nevirapine
concentrations and AUC 0–12 h. A recent study reported
that hepatotoxicity was significantly associated with higher
nevirapine trough concentrations (20). An abnormally
high ALT level was also reported to be an independent
risk factor for the development of hepatotoxicity during
nevirapine-containing treatments (21). Therefore, frequent
liver enzyme monitoring is suggested to avoid nevirapineinduced toxicity.
CYP2B6 polymorphisms also reportedly influenced
nevirapine pharmacokinetic parameters (15,16,22). In
Malaysia, CYP2B6*6 has been found to occur in 13% to
26% of Malays, Chinese, Indians, and opiate-dependent
individuals; the CYP2B6*9 allele occurs in 4.6% to 10.2%
of the group; and the CYP2B6*2 allele was found in 0.8%
to 3.2% of the group (23). The consequences of these

variations are numerous, from no detectable function to
partially reduced function and also increased expression,
and, therefore, they may affect nevirapine metabolism to
3-OH NVP. Note that our study has limitations because
the study was not assessing the effect of polymorphisms.
Furthermore, we only assessed concentrations of 2-OH and
3-OH metabolites; therefore, we cannot fully characterize
the disposition of nevirapine.
In conclusion, this study demonstrates that AST level,
ALT level, and detection of 3-OH NVP are significantly
associated with nevirapine pharmacokinetic parameters.
The detection of the 3-OH metabolite may provide a useful
indicator for distinguishing CYP2B6 activity.
Acknowledgments
This work was financially supported by a Universiti Sains
Malaysia RU Grant (grant no. 1001/PSK/8620015). The
first author was supported by the Malaysia Ministry
of Health Hadiah Latihan Persekutuan. The authors
acknowledge the staff members of INFORMM (USM),
Kelantan, and nurses and pharmacists of the Infectious
Disease Clinics of HRPZ II, HSNZ, and HSB, Malaysia, for
their support and help. Preliminary data contained in this
manuscript were presented in abstract form at the 25th
Federation of Asian Pharmaceutical Associations (FAPA)
Congress, which was held on 9–12 October 2014 in Kota
Kinabalu Sabah, Malaysia.

References
1.

MOH. Malaysian Statistics on Medicine 2009 & 2010. Petaling
Jaya, Malaysia: Ministry of Health Malaysia; 2014.

2.

Suleiman A. Global AIDS Response 2012. Kuala Lumpur,
Malaysia: Ministry of Health; 2012.

3.

MOH. Global AIDS Response Progress Report 2014. Petaling
Jaya, Malaysia: Ministry of Health Malaysia; 2014.

4.

Erickson DA, Mather G, Trager WF, Levy RH, Keirns JJ.
Characterization of the in vitro biotransformation of the HIV1 reverse transcriptase inhibitor nevirapine by human hepatic
cytochromes P-450. Drug Metab Dispos 1999; 27: 1488-1495.

5.

Lang T, Klein K, Fischer J, Nüssler AK, Neuhaus P, Hofmann
U, Eichelbaum M, Schwab M, Zanger UM. Extensive genetic
polymorphism in the human CYP2B6 gene with impact on
expression and function in human liver. Pharmacogenetics
2001; 11: 399-415.

6.

Penzak SR, Kabuye G, Mugyenyi P, Mbamanya F, Natarajan
V, Alfaro RM, Kityo C, Formentini E, Masur H. Cytochrome
P450 2B6 (CYP2B6) G516T influences nevirapine plasma
concentrations in HIV-infected patients in Uganda. HIV Med
2007; 8: 86-91.

1880

7.

Chantarangsu S, Cressey TR, Mahasirimongkol S, Capparelli
E, Tawon Y, Ngo-Giang-Huong N, Jourdain G, Lallemant M,
Chantratita W. Influence of CYP2B6 polymorphisms on the
persistence of plasma nevirapine concentrations following
a single intra-partum dose for the prevention of mother to
child transmission in HIV-infected Thai women. J Antimicrob
Chemoth 2009; 64: 1265-1273.

8.

Rotger M, Colombo S, Furrer H, Bleiber G, Buclin T, Lee BL,
Keiser O, Biollaz J, Décosterd L, Telenti A. Influence of CYP2B6
polymorphism on plasma and intracellular concentrations and
toxicity of efavirenz and nevirapine in HIV-infected patients.
Pharmacogenet Genom 2005; 15: 1-5.

9.

Suzana M, Nazirah WYW, Badriah HN. Development
and validation of HPLC-UV method for simultaneous
determination of nevirapine, 2-OH nevirapine and 3-OH
nevirapine in human plasma. International Journal of
PharmTech Research 2014; 6: 49.

10.

Fan-Havard P, Liu Z, Chou M, Ling Y, Barrail-Tran A, Haas
DW, Taburet AM. Pharmacokinetics of phase I nevirapine
metabolites following a single dose and at steady state.
Antimicrob Agents Ch 2013; 57: 2154-2160.

MUSTAFA et al. / Turk J Med Sci
11.

Cammett AM, MacGregor TR, Wruck JM, Felizarta F,
Miailhes P, Mallolas J, Piliero PJ. Pharmacokinetic assessment
of nevirapine and metabolites in human immunodeficiency
virus type 1-infected patients with hepatic fibrosis. Antimicrob
Agents Ch 2009; 53: 4147-4152.

18.

Elsherbiny D, Cohen K, Jansson B, Smith P, McIlleron H,
Simonsson USH. Population pharmacokinetics of nevirapine in
combination with rifampicin-based short course chemotherapy
in HIV- and tuberculosis-infected South African patients. Eur
J Clin Pharmacol 2009; 65: 71-80.

12.

de Vries-Sluijs TEMS, Dieleman JP, Arts D, Huitema ADR,
Beijnen JH, Schutten M, van der Ende ME. Low nevirapine
plasma concentrations predict virological failure in an
unselected HIV-1-infected population. Clin Pharmacokinet
2003; 42: 599-605.

19.

Moltó J, Valle M, Miranda C, Cedeño S, Miranda J, Santos JR,
Negredo E, Vilaró J, Costa J, Clotet B. Once- or twice-daily
dosing of nevirapine in HIV-infected adults: A population
pharmacokinetics approach. J Antimicrob Chemoth 2008; 62:
784-792.

13.

Kappelhoff BS, Crommentuyn KML, de Maat MMR, Mulder
JW, Huitema ADR, Beijnen JH. Practical guidelines to
interpret plasma concentrations of antiretroviral drugs. Clin
Pharmacokinet 2004; 43: 845-853.

20.

Wang J, Kou H, Fu Q, Han Y, Qiu Z, Zuo L, Li Y, Zhu Z, Ye M,
Ma Q et al. Nevirapine plasma concentrations are associated
with virologic response and hepatotoxicity in Chinese patients
with HIV infection. PLoS One 2011; 6: e26739.

14.

Arroyo E, Valenzuela B, Portilla J, Climent-Grana E, PérezRuixo JJ, Merino E. Pharmacokinetics of methadone in
human-immunodeficiency-virus-infected patients receiving
nevirapine once daily. European J Clin Pharmacol 2007; 63:
669-675.

21.

Martínez E, Blanco JL, Arnaiz JA, Pérez-Cuevas JB, Mocroft
A, Cruceta A, Marcos MA, Milinkovic A, García-Viejo MA,
Mallolas J et al. Hepatotoxicity in HIV-1-infected patients
receiving nevirapine-containing antiretroviral therapy. AIDS
2001; 15: 1261-1268.

15.

Kharasch ED, Regina KJ, Blood J, Friedel C. Methadone
pharmacogenetics: CYP2B6 polymorphisms determine plasma
concentrations, clearance, and metabolism. Anesthesiology
2015; 123: 1142-1153.

22.

16.

de Maat MMR, Huitema ADR, Mulder JW, Meenhorst PL,
van Gorp ECM, Beijnen JH. Population pharmacokinetics
of nevirapine in an unselected cohort of HIV-1-infected
individuals. Brit J Clin Pharmaco 2002; 54: 378-385.

Saitoh A, Sarles E, Capparelli E, Aweeka F, Kovacs A,
Burchett SK, Wiznia A, Nachman S, Fenton T, Spector SA.
CYP2B6 genetic variants are associated with nevirapine
pharmacokinetics and clinical response in HIV-1-infected
children. AIDS 2007; 21: 2191-2199.

23.

Musa N, Zulkafli MI, Talib N, Mohamad N, Fauzi H, Ismail
R. Haplotypes frequencies of CYP2B6 in Malaysia. J Postgrad
Med 2012; 58: 235-241.

17.

Brown KC, Hosseinipour MC, Hoskins JM, Thirumaran RK,
Tien H, Weigel R, Tauzie J, Shumba I, Schuetz EG, McLeod HL
et al. Exploration of CYP450 and drug transporter genotypes
and correlations with nevirapine exposure in Malawians.
Pharmacogenomics 2012; 13: 113-121.

1881

